Cord-blood derived treatment obtains EU orphan designation

03/12/2009 | Globes (Israel)

The European Commission has given orphan drug status to StemEx, an experimental treatment for acute forms of lymphoblastic leukemia and myeloid leukemia from Gamida Cell and Teva Pharmaceutical Industries. StemEx is produced from expanded stem/progenitor cells combined with nonexpanded cells that are both extracted from umbilical cord blood.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX